Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imaging BiometricsLSE:IBAI +11.57% Cyclically Adjusted PB Ratio is 0.68 as of Aug. 07, 2026, which is 20% below its 10-year median of 0.85. The stock has 3 warning signs investors should review. Among 354 Healthcare Providers & Services companies, Imaging Biometrics ranks better than 72.6% on this metric.
The historical rank and industry rank for Imaging Biometrics's Cyclically Adjusted PB Ratio or its related term are showing as below:
LSE:IBAI'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.09 Med: 0.85 Max: 5.55
Current: 0.91
During the past 13 years, Imaging Biometrics's highest Cyclically Adjusted PB Ratio was 5.55. The lowest was 0.09. And the median was 0.85.
LSE:IBAI's Cyclically Adjusted PB Ratio is ranked better than 72.6% of 354
companies
in the Healthcare Providers & Services industry
Industry Median: 1.845
vs LSE:IBAI: 0.91
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Imaging Biometrics's adjusted book value per share data of for the fiscal year that ended in Dec25 was £0.002. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is £0.01 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Imaging Biometrics (LSE:IBAI) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Imaging Biometrics Cyclically Adjusted PB Ratio Related Terms
Imaging Biometrics Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Imaging Biometrics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imaging Biometrics Cyclically Adjusted PB Ratio Chart
LSE:IBAI vs VEEV, BTSG, HQY: Cyclically Adjusted PB Ratio Comparison
For the Health Information Services subindustry, Imaging Biometrics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imaging Biometrics Cyclically Adjusted PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Imaging Biometrics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Imaging Biometrics's Cyclically Adjusted PB Ratio falls into.
Imaging Biometrics Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Imaging Biometrics's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.68 mean?
Imaging Biometrics (LSE:IBAI) has a Cyclically Adjusted PB Ratio of 0.68 as of Aug. 07, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Imaging Biometrics and its competitors. This is 20% below median its historical median of 0.85. Over the past decade, Imaging Biometrics' Cyclically Adjusted PB Ratio has ranged from 0.09 to 5.55. According to the industry distribution chart, Imaging Biometrics ranks #97 out of 354 companies in the Healthcare Providers & Services industry, placing it in the top 27.4%.
Is Imaging Biometrics' Cyclically Adjusted PB Ratio too high?
Imaging Biometrics' current Cyclically Adjusted PB Ratio of 0.68 is 20% below median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 5.55. The Healthcare Providers & Services industry median Cyclically Adjusted PB Ratio is 1.85. Imaging Biometrics' value of 0.68 is 63.1% below this industry median. Based on the distribution chart, Imaging Biometrics ranks #97 out of 354 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Imaging Biometrics' Cyclically Adjusted PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Imaging Biometrics ranks #97 out of 354 companies for Cyclically Adjusted PB Ratio. This puts Imaging Biometrics in the upper half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.85. Imaging Biometrics' value of 0.68 is 63.1% below this benchmark. Historically, Imaging Biometrics' own Cyclically Adjusted PB Ratio has ranged from 0.09 to 5.55 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 1.85, Imaging Biometrics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Healthcare Providers & Services company?
The median Cyclically Adjusted PB Ratio among Healthcare Providers & Services companies is 1.85, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imaging Biometrics's current Cyclically Adjusted PB Ratio of 0.68 is 63.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Imaging Biometrics and its competitors. For the Healthcare Providers & Services industry, the median Cyclically Adjusted PB Ratio is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imaging Biometrics's current Cyclically Adjusted PB Ratio is 0.68, which is 20% below median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imaging Biometrics stock overvalued right now?
Imaging Biometrics (LSE:IBAI) has a current Cyclically Adjusted PB Ratio of 0.68. The current Cyclically Adjusted PB Ratio is 0.68, which is 20% below median its 10-year median of 0.85 and 63.1% below the Healthcare Providers & Services industry median of 1.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Imaging Biometrics (LSE:IBAI), the current Cyclically Adjusted PB Ratio is 0.68 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imaging Biometrics Ltd formerly, IQ-AI Ltd operates as an investment company. The principal activity of the group is the provision of convenient, cost-effective, and clinical treatments to patients in the field of medical imaging diagnostics, based on technologies. Its geographical segment includes United Kingdom, Switzerland, European Union, and the United States of America and reportable segments are holding company expenses, medical software, Oral GaM and organ-on-a-chip. The company derives a majority of its revenue from the United States of America. It also supplies medical technology solutions and has a neuroimaging product portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IBAI has been successfully added to your 
